Replies to post #341420 on Innovation Pharmaceuticals Inc (IPIX)

[Jhawker]

But not the South African variant

[frenchbroad]

Yes this news has relation to Ipix but is not a surprise. *The two-dose regimen of the Moderna COVID-19 Vaccine at the 100 µg dose is expected to be protective against emerging strains detected to date. Nonetheless, Moderna today announced its clinical strategy to proactively address the pandemic as the virus continues to evolve. First, the Company will test an additional booster dose of its COVID-19 Vaccine (mRNA-1273) to study the ability to further increase neutralizing titers against emerging strains beyond the existing primary vaccination series. Second, the Company is advancing an emerging variant booster candidate (mRNA-1273.351) against the B.1.351 variant first identified in the Republic of South Africa.* And from the Moderna chef *“As we seek to defeat the COVID-19 virus, which has created a worldwide pandemic, we believe it is imperative to be proactive as the virus evolves.* It means only than there will be need for new vaccine and boosters every year or months. And it means direct anti-viral par example Brilacidin must also be part of the solution.